- Profile
- prev
- next
General
-
Headquarters
Cambridge, Massachusetts, United States
-
Founders & Team
Alan Crane, David Goldfarb, David Sabatini
-
Year Founded
2009
-
Number of employees
50
-
Company type
Private company
-
Total funding ($M)
98.2
-
Investors
Longevity Fund, Atlas Venture, Brace Pharma Capital, Johnson & Johnson Development Corporation, Polaris Partners, SR One
Technical Details
-
Disease indication
autosomal dominant polycystic kidney disease
-
Product modality
small molecule drugs
About
The leading mTORC1 platform company, is developing targeted therapeutics designed to help patients increase their healthy years for uninterrupted quality of life.
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders.